New eczema drug shows promise in early trial
Disease control
Completed
This study tested a new medicine called camoteskimab in 62 adults with moderate to severe eczema (atopic dermatitis). The goal was to see if it reduces skin redness, itching, and rash better than a placebo over 12 weeks. Participants received either the drug or a placebo, and som…
Phase: PHASE2 • Sponsor: Apollo Therapeutics Ltd • Aim: Disease control
Last updated May 13, 2026 16:02 UTC